Preferred Label : Anti-ULBP6 Monoclonal Antibody 23ME-01473;
NCIt definition : An Fc effector-enhanced, humanized afucosylated monoclonal antibody directed against
the natural-killer group 2, member D receptor protein (NKG2D or KLRK1) ligand UL16-binding
protein 6 (ULBP6), with potential immunostimulating and antineoplastic activities.
Upon administration, anti-ULBP6 monoclonal antibody 23ME-01473 targets and binds to
soluble form of ULBP6, thereby preventing the binding of soluble ULBP6 to NKG2D-expressing
immune cells. This enhances the binding of NKG2D-expressing immune cells, including
natural killer (NK) cells and subset of T-cells, to ULBP6-expressing tumor cells,
which leads to the activation of NK cells and T-cells, the secretion of interferon-gamma
(IFNg), and the lysis of tumor cells. In addition, the afucosylated Fc domain of 23ME-01473
binds to the activating Fc receptor low affinity immunoglobulin gamma Fc region receptor
III-A (FcgammaRIIIA; CD16a) expressed on NK cells, which enhances antitumor response
through antibody-dependent cell-mediated cytotoxicity (ADCC). ULBP6 is a stress-induced
cell surface NKG2D ligand overexpressed on cancer cells. The shedding of ULBP6 from
tumor cell surface to produce the soluble form allows tumor cells to evade NKG2D-expressing
immune cells. 23ME-01473 also targets and binds to ULBP2 and ULBP5, blocking their
interaction with NKG2D.;
Molecule name : 23ME-01473; 23ME 01473;
Origin ID : C209762;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
